LIFEVANTAGE CORP Dividends Paid
LIFEVANTAGE CORP (LFVN) reported Dividends Paid of $2.34 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDividends · last filed 2026-08-27
- LIFEVANTAGE CORP payments of dividends for the quarter ending 2026-06-30 was $625.00K, a 11.21% increase year-over-year.
- LIFEVANTAGE CORP payments of dividends for the quarter ending 2026-03-31 was $573.00K, a 13.92% increase year-over-year.
- LIFEVANTAGE CORP payments of dividends for the quarter ending 2025-12-31 was $575.00K, a 14.54% increase year-over-year.
- LIFEVANTAGE CORP payments of dividends for the quarter ending 2025-09-30 was $571.00K, a 14.20% increase year-over-year.
- LIFEVANTAGE CORP payments of dividends for fiscal 2026 was $2.34M, a 13.40% increase from fiscal 2025.
- LIFEVANTAGE CORP payments of dividends for fiscal 2025 was $2.07M, a 70.22% decline from fiscal 2024.
- LIFEVANTAGE CORP payments of dividends for fiscal 2024 was $6.94M, a 337.58% increase from fiscal 2023.
- LIFEVANTAGE CORP payments of dividends for fiscal 2023 was $1.59M, a 319.58% increase from fiscal 2022.
| Period end | Payments of Dividends 3 month | Payments of Dividends 6 month | Payments of Dividends 9 month | Payments of Dividends 12 month |
|---|---|---|---|---|
| 2026-06-30 | $625.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $1.20M derived: sum of 2 quarters · filed 2026-08-27 | $1.77M derived: sum of 3 quarters · filed 2026-08-27 | $2.34M 10-K · filed 2026-08-27 |
| 2026-03-31 | $573.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $1.15M derived: sum of 2 quarters · filed 2026-05-06 | $1.72M 10-Q · filed 2026-05-06 | $2.28M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-12-31 | $575.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $1.15M 10-Q · filed 2026-02-04 | $1.71M derived: sum of 3 quarters · filed 2026-08-27 | $2.21M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-09-30 | $571.00K 10-Q · filed 2025-11-04 | $1.13M derived: sum of 2 quarters · filed 2026-08-27 | $1.64M derived: sum of 3 quarters · filed 2026-08-27 | $2.14M derived: sum of 4 quarters · filed 2026-08-27 |
| 2025-06-30 | $562.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-27 | $1.06M derived: sum of 2 quarters · filed 2026-08-27 | $1.57M derived: sum of 3 quarters · filed 2026-08-27 | $2.07M 10-K · filed 2026-08-27 |
| 2025-03-31 | $503.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $1.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.50M 10-Q · filed 2026-05-06 | $2.01M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $1.00M 10-Q · filed 2026-02-04 | $1.50M derived: sum of 3 quarters · filed 2026-02-04 | $1.95M derived: sum of 4 quarters · filed 2026-02-04 |
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-04 | $1.00M derived: sum of 2 quarters · filed 2025-11-04 | $1.45M derived: sum of 3 quarters · filed 2025-11-04 | $1.91M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-04 | $951.00K derived: sum of 2 quarters · filed 2025-09-04 | $1.41M derived: sum of 3 quarters · filed 2025-09-04 | $6.94M 10-K · filed 2025-09-04 |
| 2024-03-31 | $448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-06 | $903.00K derived: sum of 2 quarters · filed 2025-05-06 | $6.44M 10-Q · filed 2025-05-06 | $6.88M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $455.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-05 | $5.99M 10-Q · filed 2025-02-05 | $6.43M derived: sum of 3 quarters · filed 2025-02-05 | $6.82M derived: sum of 4 quarters · filed 2025-02-05 |
| 2023-09-30 | $5.53M 10-Q · filed 2024-10-29 | $5.98M derived: sum of 2 quarters · filed 2024-10-29 | $6.36M derived: sum of 3 quarters · filed 2024-10-29 | $6.74M derived: sum of 4 quarters · filed 2024-10-29 |
| 2023-06-30 | $445.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-28 | $828.00K derived: sum of 2 quarters · filed 2024-08-28 | $1.21M derived: sum of 3 quarters · filed 2024-08-28 | $1.59M 10-K · filed 2024-08-28 |
| 2023-03-31 | $383.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-02 | $764.00K derived: sum of 2 quarters · filed 2024-05-02 | $1.14M 10-Q · filed 2024-05-02 | $1.52M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $381.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-01-30 | $758.00K 10-Q · filed 2024-01-30 | $1.14M derived: sum of 3 quarters · filed 2024-01-30 | $1.14M derived: sum of 4 quarters · filed 2024-01-30 |
| 2022-09-30 | $377.00K 10-Q · filed 2023-11-09 | $755.00K derived: sum of 2 quarters · filed 2023-11-09 | $755.00K derived: sum of 3 quarters · filed 2023-11-09 | $755.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $378.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-28 | $378.00K derived: sum of 2 quarters · filed 2023-08-28 | $378.00K derived: sum of 3 quarters · filed 2023-08-28 | $378.00K 10-K · filed 2023-08-28 |
| 2022-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | $0.00 10-Q · filed 2023-05-04 | |
| 2021-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-02 | $0.00 10-Q · filed 2023-02-02 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $0.00 10-K · filed 2022-08-23 | |||
| 2020-06-30 | $0.00 10-K · filed 2022-08-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |